University of Groningen

Author's reply: Baloxavir for influenza

de Haas, Esther C; Luijendijk, Hendrika J

Published in:
European Journal of Internal Medicine

DOI:
[10.1016/j.ejim.2019.12.021](https://doi.org/10.1016/j.ejim.2019.12.021)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

de Haas, E. C., & Luijendijk, H. J. (2020). Author's reply: Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. . *European Journal of Internal Medicine*, 72, 102.
<https://doi.org/10.1016/j.ejim.2019.12.021>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Letter to the Editor

Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. Author's reply.

ARTICLE INFO

Keywords:

Clinical trial
Enrichment
Generalisability
Baloxavir
Influenza

In response to our comment [1], Dr Portsmouth and colleagues provide additional information about the results of the CAPSTONE-1 trial [2], which we appreciate. In our comment, we underlined that the composition of the study population should have been taken into account when the study results were analysed, interpreted and presented.

The authors confirm that enrichment of the study population may have occurred. They explain that the combination of competitive enrolment and an earlier start of the influenza season in Japan has led to relatively few North-American adult participants. Since a previous population pharmacokinetic analysis has shown a difference in plasma baloxavir exposure between Asians and non-Asians [3,4], the question is why the research team did not choose a design with stratified enrolment per country.

The authors also confirm that CAPSTONE-1 did not show a reduction in time to alleviation of flu symptoms in North-American adults treated with baloxavir compared to placebo. They postulate that a baseline imbalance in eight potential prognostic factors has likely contributed to the lack of effect. Yet, the adjusted analysis, which they now present, leaves the lack of effect largely unexplained: the point estimate changed from -2.1 h to -5.2 h [5].

Furthermore, the authors hypothesise that the lack of effect of baloxavir in North-American adults may be due to a lack of power. We agree that the precision of the estimated effect size is lower with a smaller sample size. However, given the 95% confidence intervals around the time to alleviation of flu symptoms in both study groups and the overlap between them (baloxavir 66.2–94.0; placebo 62.7–125.8), it seems unlikely that a trial with a larger number of North-American adults will yield a difference between baloxavir and placebo that would approximate the observed effect of -27.2 h in the Japanese adults.

Finally, the authors claim that baloxavir was effective in North-American adults in the CAPSTONE-2 trial, of which the full results have

not been published [6]. However, this trial was performed in patients at an increased risk of influenza complications. To proof that baloxavir has a clinically relevant effect on the time to alleviation of flu symptoms in *otherwise healthy North-American adults with uncomplicated influenza*, the target indication in CAPSTONE-1, one or more additional trials will need to be performed.

Declaration of Competing Interest

None.

References

- [1] de Haas, Esther C. et al. Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. *European Journal of Internal Medicine*, Volume 62, e8–e9.
- [2] Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. *N Engl J Med* 2018;379:913–23.
- [3] Japanese Pharmaceuticals and Medical Devices Agency. Review Report Xofluza 10 mg and 20 mg 2018 8 February Available via: www.pmda.go.jp/files/000225380.pdf.
- [4] Genentech USA, Inc. XOFLUZA™ (baloxavir marboxil) [label]. 2018. Available via: www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf.
- [5] Portsmouth S, Kawaguchi K, Uehara T, Hayden F. Re Baloxavir for influenza: enrichment obscured lack of effect in North-American adults. *Eur J Int Med*. 2019. this issue.
- [6] Ison MG, Portsmouth S, Yoshida Y, Shishido T, Hayden F, Uehara T. LB16: phase 3 trial of Baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 study). *Open Forum Infect Dis* 2018;5(Suppl1):S764–5.

Esther C. de Haas*, Hendrika J. Luijckendijk
University Medical Centre Groningen, University of Groningen, Department
of General Practice and Elderly Care Medicine, PO Box 196, 9700 AD
Groningen, the Netherlands
E-mail address: e.de.haas@umcg.nl (E.C. de Haas).

DOI of original article: <https://doi.org/10.1016/j.ejim.2018.12.002>

* Corresponding author.

<https://doi.org/10.1016/j.ejim.2019.12.021>

Received 19 December 2019; Accepted 23 December 2019

Available online 03 January 2020

0953-6205/© 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.